

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A substantially pure peptide having the amino acid sequence CKQAGESCDIFSQNCCVG-TCAFICIE-NH<sub>2</sub> (SEQ ID NO 1).
2. (Original) A substantially pure peptide of claim 1, wherein the peptide is used a sodium channel modulator.
3. (Currently Amended) A process of preparing substantially pure peptide of claim 1, comprising of:
  - (i) isolation of the peptide, and
  - (ii) purifying the peptide by chromatographic methods[[ , ]] .
4. (Original) A process of preparing substantially pure peptide of claim 3, wherein the peptide in step (i) is isolated from venoms of a molluscivorous snail.
5. (Original) A process of preparing substantially pure peptide of claim 4, wherein the molluscivorous snail is *Conus amadis*.
6. (Original) A process of preparing substantially pure peptide of claim 3, wherein the purification step (ii) is carried out by HPLC (High Performance Liquid Chromatography).
7. (Original) A substantially pure peptide of claim 1, wherein the peptide is used for treatment neurophysiological and neurological disorders.
8. (Original) A substantially pure peptide of claim 7, wherein the peptide is used for treatment neurophysiological and neurological disorders n schizophrenia, epilepsy, bipolar disorder or in syndromes that affect the nervous system.

9. (Original) A pharmaceutical composition comprising a peptide having the amino acid sequence CKQAGESCDIFSQNCCVG-TCAFICIE-NH<sub>2</sub> (SEQ ID NO 1) with or without pharmaceutically acceptable carriers.

10. (New) A method of treating neurophysiological and neurological disorders including schizophrenia, epilepsy, bipolar disorder and syndromes that affect the nervous system, said method comprising step of administering pharmaceutically effective amount of peptide of SEQ ID NO: 1 or pharmaceutical composition comprising said peptide.